Carolyn Evan

827 total citations
20 papers, 527 citations indexed

About

Carolyn Evan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Carolyn Evan has authored 20 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Carolyn Evan's work include Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). Carolyn Evan is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). Carolyn Evan collaborates with scholars based in United States, Italy and Australia. Carolyn Evan's co-authors include Kathryn P. Gray, Christopher J. Sweeney, Philip W. Kantoff, Mari Nakabayashi, Anis Hamid, Grace Shaw, Massimo Loda, Eliezer M. Van Allen, Laura E. MacConaill and Niall M. Corcoran and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Carolyn Evan

20 papers receiving 526 citations

Peers

Countries citing papers authored by Carolyn Evan

Since Specialization

Citations

This map shows the geographic impact of Carolyn Evan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolyn Evan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolyn Evan more than expected).

Fields of papers citing papers by Carolyn Evan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolyn Evan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolyn Evan. The network helps show where Carolyn Evan may publish in the future.

Co-authorship network of co-authors of Carolyn Evan

This figure shows the co-authorship network connecting the top 25 collaborators of Carolyn Evan. A scholar is included among the top collaborators of Carolyn Evan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolyn Evan. Carolyn Evan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases 2020 ·Prostate Cancer and Prostatic Diseases ·Bradley A. McGregor, Li Zhang, Kathryn P. Gray, Grace Shaw, Carolyn Evan, Edoardo Francini, Christopher J. Sweeney	5
2	Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer 2020 ·The Prostate ·Cécile Vicier, Praful Ravi, Lucia Kwak, Lillian Werner, Ying Huang, Carolyn Evan, Massimo Loda, Anis Hamid, Christopher J. Sweeney	16
3	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry 2019 ·Prostate Cancer and Prostatic Diseases ·Edoardo Francini, Kathryn P. Gray, Grace Shaw, Carolyn Evan, Anis Hamid, (unknown), Philip W. Kantoff, Mary‐Ellen Taplin, Christopher J. Sweeney	44
4	Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC). 2019 ·Journal of Clinical Oncology ·Cécile Vicier, Wanling Xie, Anis Hamid, Carolyn Evan, Christopher J. Sweeney	1
5	Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP). 2019 ·Journal of Clinical Oncology ·Cécile Vicier, Lillian Werner, Ying Huang, Anis Hamid, Carolyn Evan, Massimo Loda, Christopher J. Sweeney	5
6	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer 2018 ·European Urology ·Anis Hamid, Kathryn P. Gray, Grace Shaw, Laura E. MacConaill, Carolyn Evan, Brandon Bernard, Massimo Loda, Niall M. Corcoran, Eliezer M. Van Allen, Atish D. Choudhury, Christopher J. Sweeney	178
7	Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry. 2018 ·Journal of Clinical Oncology ·Edoardo Francini, Kathryn P. Gray, Grace Shaw, Carolyn Evan, Anis Hamid, (unknown), Philip W. Kantoff, Mary‐Ellen Taplin, Christopher J. Sweeney	1
8	Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases. 2018 ·Journal of Clinical Oncology ·Li Zhang, Kathryn P. Gray, Grace Shaw, Carolyn Evan, Edoardo Francini, Christopher J. Sweeney	1
9	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer 2017 ·Clinical Genitourinary Cancer ·Edoardo Francini, Steven Yip, (unknown), Haocheng Li, (unknown), Carolyn Evan, Marina D. Kaymakcalan, Grace Shaw, Philip W. Kantoff, Mary‐Ellen Taplin, Nimira Alimohamed, Anthony M. Joshua, Daniel Y.C. Heng, Christopher J. Sweeney	16
10	Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry 2017 ·Annals of Oncology ·Edoardo Francini, Steven Yip, Neesar Ahmed, (unknown), (unknown), Carolyn Evan, Marina D. Kaymakcalan, Grace Shaw, Philip W. Kantoff, Mary‐Ellen Taplin, Nimira Alimohamed, Anthony M. Joshua, D.Y.C. Heng, Christopher J. Sweeney	3
11	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center 2015 ·Clinical Genitourinary Cancer ·Vinayak Muralidhar, Meredith M. Regan, Lillian Werner, Mari Nakabayashi, Carolyn Evan, Joaquim Bellmunt, Toni K. Choueiri, Aymen Elfiky, Lauren C. Harshman, Rana R. McKay, Mark M. Pomerantz, Christopher J. Sweeney, Mary‐Ellen Taplin, Philip W. Kantoff, Paul L. Nguyen	8
12	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease 2015 ·The Journal of Urology ·Che‐Kai Tsao, Kathryn P. Gray, Mari Nakabayashi, Carolyn Evan, Philip W. Kantoff, Jiaoti Huang, Matthew D. Galsky, Mark M. Pomerantz, William Oh	51
13	Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less 2014 ·Clinical Genitourinary Cancer ·Arti Parekh, Ming‐Hui Chen, Powell L. Graham, Brandon A. Mahal, Ariel E. Hirsch, Mari Nakabayashi, Carolyn Evan, Philip W. Kantoff, Neil E. Martin, Paul L. Nguyen	15
14	Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival 2014 ·The Prostate ·(unknown), Kathryn P. Gray, Lauren C. Harshman, Carolyn Evan, Mari Nakabayashi, Raina N. Fichorova, Jennifer R. Rider, Lorelei A. Mucci, Philip W. Kantoff, Christopher J. Sweeney	70
15	Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. 2013 ·Journal of Clinical Oncology ·(unknown), Kathryn P. Gray, Mari Nakabayashi, Carolyn Evan, Elizabeth O’Donnell, Mark M. Pomerantz, Philip W. Kantoff, Christopher J. Sweeney	5
16	Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival 2013 ·The Prostate ·(unknown), Kathryn P. Gray, Carolyn Evan, Mari Nakabayashi, Raina N. Fichorova, Jennifer R. Rider, Lorelei A. Mucci, Philip W. Kantoff, Christopher J. Sweeney	35
17	Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality 2011 ·Cancer Prevention Research ·Mark M. Pomerantz, Lillian Werner, Wanling Xie, Meredith M. Regan, Gwo‐Shu Mary Lee, Tong Sun, Carolyn Evan, (unknown), Mari Nakabayashi, William Oh, Philip W. Kantoff, Matthew L. Freedman	32
18	The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid 2007 ·Cancer ·William Oh, (unknown), Mari Nakabayashi, Carolyn Evan, (unknown), Timothy J. Daskivich, (unknown), Michael Smith, Maureen P. Neary, Mei Sheng Duh	36
19	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC) 2005 ·Journal of Clinical Oncology ·(unknown), Meredith M. Regan, (unknown), Carolyn Evan, Philip W. Kantoff, Mary‐Ellen Taplin, Oliver Sartor, William Oh	1
20	CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA) 2005 ·Value in Health ·William Oh, (unknown), (unknown), Carolyn Evan, (unknown), (unknown), Melissa Smith, (unknown), (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact